COMMUNIQUÉS West-GlobeNewswire

FOXO TECHNOLOGIES INC.’S SUBSIDIARY, MYRTLE RECOVERY CENTERS, INC., ANNOUNCES EXPANSION OF ITS FLAGSHIP FACILITY AND FOCUS ON SUBSTANCE USE DISORDER PATIENTS WITH RELATED MEDICAL CARE NEEDS
19/10/2026
WEST PALM BEACH, FL, Oct. 19, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.’s (OTC: FOXO) (“FOXO”) is pleased to announce that its subsidiary, Myrtle Recovery Centers, Inc. (“Myrtle”), recently received its license [...]
Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress
19/10/2026
Three Studies Selected for Oral Presentation, Including a Late-Breaking Abstract; Data Highlight Durable Responses and Long-Term Survival Signals Across Immunologically Cold Tumors and Deep, Sustained Responses in [...]
Baylor Genetics to Highlight Clinical and Diagnostic Utility of Genome Sequencing at the 2026 American Society of Human Genetics Annual Meeting
19/10/2026
HOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics , a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, today announced it will share new [...]
Strata Earns HFMA Peer Review Designation for 13 Consecutive Years
19/10/2026
Recognition reflects Strata’s commitment to delivering customer value and advancing healthcare financial decision-making CHICAGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Strata Decision Technology today announced that after [...]
Alignment Health Plan and Astrana Health Partner to Expand Access to Trusted Local Care for California Seniors
19/10/2026
New collaboration expands access to multilingual, community-based care across seven Northern and Southern California counties ORANGE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Alignment Health Plan, an award-winning [...]
VIRBAC: Solide croissance de +7,9 % à TCC à fin septembre 2026, portée par la croissance à deux chiffres de nos plateformes Supercharge
19/10/2026
Le chiffre d'affaires à fin septembre 2026 atteint 1 168 millions d'euros : +7,9 % à taux de change et périmètre constants (PCC) par rapport à fin septembre 2025 +5,9 % à taux réels, impacté par des effets de change [...]
VIRBAC: Solid growth of +7.9% at CERS in YTD September 2026, fueled by double-digit growth of our Supercharge platforms
19/10/2026
End of September 2026 revenue reached €1,168 million : +7.9% at constant exchange rate and scope (at CERS) vs YTD September 2025 +5.9% at actual rates impacted by currency headwinds Balanced growth in both segments: [...]
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
19/10/2026
PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application ( [...]
Ritedose Partners with Newberry College to Launch Leadership Development Program
19/10/2026
Organizational development and pharmaceutical leadership certificate is designed to strengthen organizational leadership at Ritedose COLUMBIA, S.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose) [...]
Novo Nordisk A/S - share repurchase programme
19/10/2026
Bagsværd, Denmark, 19 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
19/10/2026
TORONTO, ONTARIO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) is pleased to announce the publication of a new corporate presentation, now [...]
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
19/10/2026
• Late-breaking poster will present data from the first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers SYDNEY, AUSTRALIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Immutep [...]
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
19/10/2026
Phase 2 data from the ADDRESS-LC trial of Bezisterim demonstrated statistically significant improvements versus placebo across fatigue, post-exertional malaise, and objective cognitive measures in Long COVID patients [...]
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
19/10/2026
Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature [...]
Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
19/10/2026
Latest addition to Resmed’s growing fabric mask portfolio combines a soft, breathable fabric cushion with a minimalist design for greater comfort and choice SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD [...]
Hyperion DeFi Schedules Third Quarter Earnings Call for Thursday, November 12 at 8:00 a.m. ET
19/10/2026
LAGUNA HILLS, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that it [...]
Medera's Novoheart Technology Powers Advanced Human Cardiac Disease Modeling at Singapore's New CIPHER Research Centre
19/10/2026
National Heart Centre Singapore's new research centre integrates Novoheart's proprietary Heart-in-a-Jar technology with patient-derived cardiac disease models to advance cardiovascular research and drug discovery [...]
Rivus Pharmaceuticals to Present Preclinical Obesity Data for Muscle-Preserving, Oral GLP-1 RV-8451 at ObesityWeek®
19/10/2026
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health, today [...]
Syncromune to Present Updated Long-Term Overall Survival Data from Phase 1 Trial of SYNC-T Therapy SV-102 in Metastatic Prostate Cancer at ESMO Congress 2026
19/10/2026
FORT LAUDERDALE, Fla., and WEST DES MOINES, Iowa, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Syncromune, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™ an investigational in situ multi-target [...]

Pages